Recent Quotes
My Watchlist
Indicators
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

1.670 +0.070 (+4.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Prelude Therapeutics Incorporated - Common Stock

< Previous 1 2 Next >
News headline image
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
From FN Media Group LLC
Via GlobeNewswire
News headline image
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Prelude Therapeutics Announces Strategic Business Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Citizens Life Sciences Conference
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Announces Presentations at 2025 AACR Annual Meeting
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST) 
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitor 
From Prelude Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>